CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

On September 6, 2022 CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, reported that management will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 (Press release, CymaBay Therapeutics, SEP 6, 2022, https://ir.cymabay.com/news/detail/541/cymabay-therapeutics-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference [SID1234619015]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference

Arbutus to Participate in September Investor Conferences

On September 6, 2022 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, reported that the Company will participate in the following upcoming investor conferences taking place in New York (Press release, Arbutus Biopharma, SEP 6, 2022, View Source [SID1234619014]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)

Company Presentation: Tuesday, September 13th at 12:30 pm ET
Presenter: William Collier, President & Chief Executive Officer
Baird’s 2022 Global Healthcare Conference (September 13-14, 2022)

Fireside Chat: Wednesday, September 14th at 10:15 am ET
Presenters: William Collier, President & Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Michael McElhaugh, Chief Business Officer; and David Hastings, Chief Financial Officer
Live webcasts of the presentation and fireside chat can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. An archived replay of the webcast will be available on the Arbutus website after the event.

Almac Sciences and UCD strengthen collaboration with prestigious SFI grant

On September 6, 2022 Almac Sciences, a member of the Almac Group, and University College Dublin (UCD), reported that they have been awarded a Science Foundation Ireland (SFI) ‘Frontiers for the Future’ grant (Press release, Almac, SEP 6, 2022, View Source [SID1234619013]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The €420,000 grant will enable the exploitation, for the first-time, of emerging enzymes such as ene-reductase (ERED) and carboxylic acid reductase (CAR) enzymes in continuous flow reactors to develop new routes to chemical products. Almac Sciences and UCD will work together to establish the use of enzymatic multi-step reactions in continuous flow reactors as readily and widely applicable tools for the sustainable synthesis of fine chemicals.

The project team, co-funded by Almac Sciences, will include one postdoctoral researcher and two PhD studentships over the next 4 years based primarily in UCD. Both PhD students, Ruairi Bannon and Philip Jamieson, have undertaken industry placements within Almac as part of their undergraduate studies. The placement has equipped them with key transferable skills and valuable insights into critical decision-making for flow processes with industrial relevance.

Lead academic at UCD, Dr Marcus Baumann said "This project will further build on our existing collaboration with Almac Sciences, strengthening expertise for continuous flow within Ireland with a focus on enhancing the application of continuous flow within the biocatalysis sphere."

Almac and UCD have collaborated on various projects over the last few years and have recently been awarded SSPC’s Industry Impact of the Year, recognising their joint development of continuous flow processes using enzymes.

Almac continues to enhance its flow service offering with a completed £500,000 investment to date already in place. This project further establishes Almac Sciences in the field of flow chemistry and builds on novel methodologies applicable for industrial scale transformations.

Dr Megan Smyth, Team Leader Custom and Flow Chemistry, Almac Sciences commented: "Collaborations such as these established with Marcus and UCD are of the utmost importance to us in Almac Sciences. By supporting development of students, we can ensure a pipeline of expertly trained flow chemists in line with our growing capabilities. For Ruairi and Philip, the opportunity to avail of expertise at Almac Sciences and UCD fosters key interdisciplinary skills and research excellence in the area of flow. I am excited to work closely with them both throughout their studies and wish them every success."

AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

On September 6, 2022 AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, reported Chris McAleer, Ph.D., Deputy Chief Science Officer of AIM, and William Mitchell, M.D. Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022 (Press release, AIM ImmunoTech, SEP 6, 2022, View Source [SID1234619012]). In addition to management’s presentations, the Company is proud to announce its sponsorship of the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: Rintatolimod (Ampligen): An Investigational Immunomodulatory Agent Targeted at Cancers of High Unmet Need
Author: Christopher McAleer, Ph.D.
Date: Saturday, September 10

Title: The Mechanism of PAMP Restricted Rintatolimod in Limiting Systemic Inflammatory Responses
Author: William M. Mitchell, M.D., Ph.D.
Date: Saturday, September 10

Presentations will take place at the Cancer Genetics & Pharmacology Building at the Roswell Park Comprehensive Center.

For more information about the conference, visit: View Source

The presentations will be available on the AIM website once presented at the conference.

Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

On September 6, 2022 Bristol Myers Squibb (NYSE: BMY) reported that the company will take part in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 in New York City (Press release, Bristol-Myers Squibb, SEP 6, 2022, View Source [SID1234619010]). Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer and Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Global Drug Development will answer questions about the company at 8:10 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source An archived edition of the session will be available later that day.